Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
PolyPeptide Group AG ( (CH:PPGN) ) just unveiled an update.
PolyPeptide Group AG has reached a significant milestone in its Malmö, Sweden facility expansion, with the installation of pre-built modules aimed at doubling its solid-phase peptide synthesis capacity. This expansion, part of a EUR ~100 million investment largely funded by a pharmaceutical partner, is designed to meet growing global demand and is expected to accelerate capacity expansion, supporting the company’s goal to double its 2023 revenue by 2028.
The most recent analyst rating on (CH:PPGN) stock is a Buy with a CHF35.00 price target. To see the full list of analyst forecasts on PolyPeptide Group AG stock, see the CH:PPGN Stock Forecast page.
More about PolyPeptide Group AG
PolyPeptide Group AG is a specialized Contract Development & Manufacturing Organization (CDMO) focusing on peptide- and oligonucleotide-based active pharmaceutical ingredients. The company supports the pharmaceutical and biotech industries, contributing to global health with a broad portfolio of products and services from pre-clinical to commercial stages. With a history dating back to 1952, PolyPeptide operates six GMP-certified facilities worldwide and is listed on the SIX Swiss Exchange.
Average Trading Volume: 34,156
Technical Sentiment Signal: Buy
Current Market Cap: CHF848.9M
For a thorough assessment of PPGN stock, go to TipRanks’ Stock Analysis page.